Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.61 |
| ▸ | PFKFB3 | Q16875 | 9/20 | 0.53 |
| ▸ | PFKFB4 | Q16877 | 8/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026445 | 0.88 | PFKFB3 (0.56) | HSD11B1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL3926760 | 0.76 | HSD11B1 (1.00) | HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL3928440 | 0.74 | HSD11B1 (0.68) | HSD11B1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL788429 | 0.72 | PFKFB3 (0.87) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| Propane SCHEMBL28642185 | 0.71 | PFKFB4 (0.94) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL27815192 | 0.71 | HSD11B1 (0.63) | HSD11B1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL3883767 | 0.71 | PFKFB4 (0.55) | HSD11B1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL27815263 | 0.70 | HSD11B1 (0.62) | HSD11B1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL794266 | 0.70 | HTT (0.59) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL788108 | 0.70 | PFKFB4 (1.00) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | HSD11B1 1/4885PFKFB3 3931/4885PFKFB4 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.